S-245 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • anti phospho smad2  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc anti phospho smad2
    c-Met and TGFβ signalling in HGF-mediated EMT of NBT-II carcinoma cells. a Bar graph displays ratio of phosphorylated proteins at 2 h post HGF compared with control. b Western blot analysis of NBT-II cells treated with escalating doses of HGF at various concentrations for 2 h. Lysates are probed with indicated antibodies. c Western blot analysis of NBT-II cells treated with 5 ng/ml of HGF. Lysates were collected at denoted time points and probed with indicated antibodies. d Western blot analysis of NBT-II cells treated with 5 ng/ml of HGF in the absence or presence of c-MET inhibitor JNJ38877605. Lysates were collected at denoted time points and probed with indicated antibodies. e Western blot analysis of nuclear (n) and cytoplasmic (c) fractions isolated from NBT-II cells treated with HGF for 2 h with or without TβRI inhibitor (A83-01, 8 μM). Lysates were collected at denoted time points and probed with indicated antibodies. f Bar chart displays ratio of pSMAD2 band intensity in nuclear (n) fractions compared with total <t>SMAD2</t> (nuclear + cytoplasmic) fractions isolated from NBT-II cells treated with HGF for 2 h with or without TβRI inhibitor (A83-01, 8 μM). Bars represent mean ± SD of three independent experiments. A two-tailed Student’s t test compares the treated cell populations, ** P
    Anti Phospho Smad2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti phospho smad2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti phospho smad2 - by Bioz Stars, 2022-08
    86/100 stars
    		  Buy from Supplier
    psmad2 s245 250 255  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc psmad2 s245 250 255
    c-Met and TGFβ signalling in HGF-mediated EMT of NBT-II carcinoma cells. a Bar graph displays ratio of phosphorylated proteins at 2 h post HGF compared with control. b Western blot analysis of NBT-II cells treated with escalating doses of HGF at various concentrations for 2 h. Lysates are probed with indicated antibodies. c Western blot analysis of NBT-II cells treated with 5 ng/ml of HGF. Lysates were collected at denoted time points and probed with indicated antibodies. d Western blot analysis of NBT-II cells treated with 5 ng/ml of HGF in the absence or presence of c-MET inhibitor JNJ38877605. Lysates were collected at denoted time points and probed with indicated antibodies. e Western blot analysis of nuclear (n) and cytoplasmic (c) fractions isolated from NBT-II cells treated with HGF for 2 h with or without TβRI inhibitor (A83-01, 8 μM). Lysates were collected at denoted time points and probed with indicated antibodies. f Bar chart displays ratio of pSMAD2 band intensity in nuclear (n) fractions compared with total <t>SMAD2</t> (nuclear + cytoplasmic) fractions isolated from NBT-II cells treated with HGF for 2 h with or without TβRI inhibitor (A83-01, 8 μM). Bars represent mean ± SD of three independent experiments. A two-tailed Student’s t test compares the treated cell populations, ** P
    Psmad2 S245 250 255, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/psmad2 s245 250 255/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    psmad2 s245 250 255 - by Bioz Stars, 2022-08
    96/100 stars
    		  Buy from Supplier
    anti atf 4 phospho s245 antibody  (Abcam)
    86
    Abcam anti atf 4 phospho s245 antibody
    c-Met and TGFβ signalling in HGF-mediated EMT of NBT-II carcinoma cells. a Bar graph displays ratio of phosphorylated proteins at 2 h post HGF compared with control. b Western blot analysis of NBT-II cells treated with escalating doses of HGF at various concentrations for 2 h. Lysates are probed with indicated antibodies. c Western blot analysis of NBT-II cells treated with 5 ng/ml of HGF. Lysates were collected at denoted time points and probed with indicated antibodies. d Western blot analysis of NBT-II cells treated with 5 ng/ml of HGF in the absence or presence of c-MET inhibitor JNJ38877605. Lysates were collected at denoted time points and probed with indicated antibodies. e Western blot analysis of nuclear (n) and cytoplasmic (c) fractions isolated from NBT-II cells treated with HGF for 2 h with or without TβRI inhibitor (A83-01, 8 μM). Lysates were collected at denoted time points and probed with indicated antibodies. f Bar chart displays ratio of pSMAD2 band intensity in nuclear (n) fractions compared with total <t>SMAD2</t> (nuclear + cytoplasmic) fractions isolated from NBT-II cells treated with HGF for 2 h with or without TβRI inhibitor (A83-01, 8 μM). Bars represent mean ± SD of three independent experiments. A two-tailed Student’s t test compares the treated cell populations, ** P
    Anti Atf 4 Phospho S245 Antibody, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti atf 4 phospho s245 antibody/product/Abcam
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti atf 4 phospho s245 antibody - by Bioz Stars, 2022-08
    86/100 stars
    		  Buy from Supplier
    phospho s245 atf4  (Millipore)
    86
    Millipore phospho s245 atf4
    c-Met and TGFβ signalling in HGF-mediated EMT of NBT-II carcinoma cells. a Bar graph displays ratio of phosphorylated proteins at 2 h post HGF compared with control. b Western blot analysis of NBT-II cells treated with escalating doses of HGF at various concentrations for 2 h. Lysates are probed with indicated antibodies. c Western blot analysis of NBT-II cells treated with 5 ng/ml of HGF. Lysates were collected at denoted time points and probed with indicated antibodies. d Western blot analysis of NBT-II cells treated with 5 ng/ml of HGF in the absence or presence of c-MET inhibitor JNJ38877605. Lysates were collected at denoted time points and probed with indicated antibodies. e Western blot analysis of nuclear (n) and cytoplasmic (c) fractions isolated from NBT-II cells treated with HGF for 2 h with or without TβRI inhibitor (A83-01, 8 μM). Lysates were collected at denoted time points and probed with indicated antibodies. f Bar chart displays ratio of pSMAD2 band intensity in nuclear (n) fractions compared with total <t>SMAD2</t> (nuclear + cytoplasmic) fractions isolated from NBT-II cells treated with HGF for 2 h with or without TβRI inhibitor (A83-01, 8 μM). Bars represent mean ± SD of three independent experiments. A two-tailed Student’s t test compares the treated cell populations, ** P
    Phospho S245 Atf4, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phospho s245 atf4/product/Millipore
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phospho s245 atf4 - by Bioz Stars, 2022-08
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    c-Met and TGFβ signalling in HGF-mediated EMT of NBT-II carcinoma cells. a Bar graph displays ratio of phosphorylated proteins at 2 h post HGF compared with control. b Western blot analysis of NBT-II cells treated with escalating doses of HGF at various concentrations for 2 h. Lysates are probed with indicated antibodies. c Western blot analysis of NBT-II cells treated with 5 ng/ml of HGF. Lysates were collected at denoted time points and probed with indicated antibodies. d Western blot analysis of NBT-II cells treated with 5 ng/ml of HGF in the absence or presence of c-MET inhibitor JNJ38877605. Lysates were collected at denoted time points and probed with indicated antibodies. e Western blot analysis of nuclear (n) and cytoplasmic (c) fractions isolated from NBT-II cells treated with HGF for 2 h with or without TβRI inhibitor (A83-01, 8 μM). Lysates were collected at denoted time points and probed with indicated antibodies. f Bar chart displays ratio of pSMAD2 band intensity in nuclear (n) fractions compared with total SMAD2 (nuclear + cytoplasmic) fractions isolated from NBT-II cells treated with HGF for 2 h with or without TβRI inhibitor (A83-01, 8 μM). Bars represent mean ± SD of three independent experiments. A two-tailed Student’s t test compares the treated cell populations, ** P

    Journal: Nature Communications

    Article Title: c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression

    doi: 10.1038/s41467-019-12241-2

    Figure Lengend Snippet: c-Met and TGFβ signalling in HGF-mediated EMT of NBT-II carcinoma cells. a Bar graph displays ratio of phosphorylated proteins at 2 h post HGF compared with control. b Western blot analysis of NBT-II cells treated with escalating doses of HGF at various concentrations for 2 h. Lysates are probed with indicated antibodies. c Western blot analysis of NBT-II cells treated with 5 ng/ml of HGF. Lysates were collected at denoted time points and probed with indicated antibodies. d Western blot analysis of NBT-II cells treated with 5 ng/ml of HGF in the absence or presence of c-MET inhibitor JNJ38877605. Lysates were collected at denoted time points and probed with indicated antibodies. e Western blot analysis of nuclear (n) and cytoplasmic (c) fractions isolated from NBT-II cells treated with HGF for 2 h with or without TβRI inhibitor (A83-01, 8 μM). Lysates were collected at denoted time points and probed with indicated antibodies. f Bar chart displays ratio of pSMAD2 band intensity in nuclear (n) fractions compared with total SMAD2 (nuclear + cytoplasmic) fractions isolated from NBT-II cells treated with HGF for 2 h with or without TβRI inhibitor (A83-01, 8 μM). Bars represent mean ± SD of three independent experiments. A two-tailed Student’s t test compares the treated cell populations, ** P

    Article Snippet: The following antibodies were used; anti-E-cadherin (BD), anti-FLAG and anti-α-tubulin (Sigma), anti-HA (Y11, Santa Cruz biotech), anti-Myc (9E10 or A14, Santa Cruz Biotech), anti-phospho-SMAD2 (S465/467, Cell Signaling), anti-Laminin-b1 (Abcam), anti-SMAD2 (L16D3, Cell Signaling), anti-β-actin (Sigma), anti-TGF-β receptor I (V-22, Santa Cruz Biotech), anti-phospho-tyrosine (clone 4G10, Millipore, 05–321), anti-Phospho-Src (Tyr 416, 2101 S, Cell Signaling), anti-c-Src (B-12, Santa Cruz Biotech), anti-phospho-ERK (P-p44/42 MAPK T202/Y204, 9101, Cell Signaling), anti-Total ERK (p44/42 MAPK, 9102, Cell Signaling), anti-p38 (Cell Signaling), p-c-MET Tyr1234/1235 (Cell Signaling) and anti-phospho-SMAD2 (S245/250/255, 3104, Cell Signaling).

    Techniques: Western Blot, Isolation, Two Tailed Test